IN THE NEWS
Press Release: Bioquell invests for future growth
Automated filling and capping systems Ten steps to preventing infection in hospitals... Award by the NHS Purchasing and Supply Agency to BIOQUELL DoH & PASA Publish report on Success of BIOQUELL System in Showcase Hospital Programme BIOQUELL assist with clean up BIOQUELL Launch new Clarus L2 HPV Generator Briefing on the outbreak of Swine Influenza Virus BIOQUELL takes top prize at the Department of Health HCAI Technology Innovation Summit BBC News Films 'New Weapons Against Hospital Bugs' at Lewisham Hospital Department of Health Press Release Robot set to tackle killer hospital bugs BIOQUELL moves to newly renovated production facility Infection Control & Hospital Epidemiology Article - Impact of Hydrogen Peroxide Vapor Room Decontamination on Clostridium difficile... BIOQUELL technology showcased in seven NHS hospitals Best foot forward for cleaner hospitals East Sussex Hospitals NHS Trust Commence Deployment of RBDS Proactive Team Gloucestershire Hospitals NHS Foundation Trust are the first UK hospital to deploy a BIOQUELL Proactive team. "Hydrogen Peroxide Vapor can control Nosocomial MRSA Outbreak" - Clinical Infectious Diseases Article Rapid Review Panel upgrades BIOQUELL technology to Level One Status Department of Health Post BIOQUELL Case Studies as "Best Practice" on website Award of Joint Material Decontamination System (US military) sub-contract Deep Cleaning Service from BIOQUELL Category III decontamination service launched |
TO: CITY EDITORS 2 October, 2007 BIOQUELL PLC Award of Joint Material Decontamination System BIOQUELL PLC (“BIOQUELL”), the UK leader in specialist bio-decontamination technology and testing/compliance services, announces that it is a member of the Teledyne Brown Engineering, Inc. (“TBE”) Team that has been awarded a contract relating to the United States Department of Defense (“DOD”) Joint Material Decontamination System (“JMDS”). The JMDS is required to have the ability to decontaminate sensitive equipment, and interiors of vehicles, aircraft, ships and fixed site facilities that have been exposed to Chemical, Biological, Radiological and Nuclear (“CBRN”) warfare agents. Users of the JMDS will include the United States Army, Navy, Air Force and Marine Corps. TBE has informed BIOQUELL that the DOD has awarded TBE the initial System Development and Demonstration (“SDD”) phase of the JMDS contract which is worth approximately $14.7 million (of which BIOQUELL’s share is expected to be some $7 million) and will last two years. The SDD phase is reimbursed on a cost plus basis. The DOD’s request for proposal dated 13 March 2007 described a SDD phase which would last two years - and requested firm prices for two production options: the low rate initial production (“LRIP”) option of 23 JMDS units and the full rate production (“FRP”) option of 1,843 units. Enquiries Nick Adams BIOQUELL PLC 01264 835 900 
|
Quick Links
|
